

Comparison between the Onabotulinum Toxin and the Abobotulinum Toxin in the Treatment of Facial Wrinkles Using Different Dosing Ratios: A Split-Face Study

Thesis

Submitted in partial fulfillment of master degree in
Dermatology, Venereology, and Andrology

By

Ahmed Ibrahim ElHodhod

M.B.,B.Ch.
Faculty of Medicine
Ain Shams University

Under Supervision of

Prof. Dr. Hanan Mohamed El Kahky

Professor of Dermatology, Venereology, and Andrology
Faculty of Medicine, Ain Shams University

Prof. Dr. Samar Abdallah Mohamed Salem

Professor of Dermatology, Venereology, and Andrology
Faculty of Medicine, Ain Shams University

*Faculty of Medicine
Ain Shams University
2014*



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا
عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ

صدق الله العظيم

سورة البقرة - آية ٣٢



Acknowledgements

First, and foremost, my deepest gratitude and thanks should be offered to "**ALLAH**", the Most Kind and Most Merciful, for giving me the strength to complete this work,

I would like to express my sincere gratitude to **Prof. Dr. Hanan Mohamed El Kahky**, Professor of Dermatology, Venereology, and Andrology, Faculty of Medicine, Ain Shams University for her continuous support and guidance for me to present this work. It really has been an honor to work under her generous supervision.

I acknowledge with much gratitude to **Prof. Dr. Samar Abdallah Mohamed Salem**, Professor of Dermatology, Venereology, and Andrology, Faculty of Medicine, Ain Shams University, for her great supervision and unlimited help to provide all facilities to accomplish this work,

 **Ahmed Ibrahim El-Hodhod**

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations	i
List of Tables	ii
List of Figures.....	vii
Introduction.....	1
Aim of the Study	3
Review of Literature	
- Wrinkles	4
• Epidemiology	5
• Classification and Grading	6
• Histopathology	8
• Etiopathogenesis	22
• Treatment approaches	30
- Botulinum Toxin.....	42
• History	41
• Biosynthesis	46
• Mechanism of action	51
• Therapeutic indications	59
• Clinical pharmacology	63
Patients and Methods.....	79
Results.....	92

List of Contents *(Cont...)*

<i>Subject</i>	<i>Page No.</i>
Discussion	146
Summary	165
Conclusion	172
Recommendations	173
References	174
Appendices	I
Arabic Summary	—

List of Abbreviations

ABO	: Abobotulinum
BTX	: Botulinum toxin
CGRP	: Calcitonin gene-related peptide
GAGs	: Glycosaminoglycans
ONA	: Onabotulinum
SVP2	: Synaptic Vesicle Protein-2
TCA	: Trichloroacetic acid
VAMP	: Vesicle associated membrane proteins

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Illustrating P-values and their significance.....	93
Table (2):	Comparison between group A and B patient's regarding their age and gender.....	94
Table (3):	Comparison of the time to improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on static posture.	100
Table (4):	Comparison of the time to improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on dynamic posture.	100
Table (5):	Comparison of the time to improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on static posture.	102
Table (6):	Comparison of the time to improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on dynamic posture.....	102
Table (7):	Comparison of the time to improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on static posture.	103

List of Tables *(Cont...)*

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (8):	Comparison of the time to improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on dynamic posture.....	104
Table (9):	Comparison of the time to improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on static posture.	105
Table (10):	Comparison of the time to improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on dynamic posture.....	105
Table (11):	Comparison of the duration of improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on static posture.	106
Table (12):	Comparison of the duration of improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on dynamic posture.....	107
Table (13):	Comparison of the duration of improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on static posture.	108

List of Tables *(Cont...)*

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (14):	Comparison of the duration of improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group A patients (ABO: ONA; 2.5: 1.0 U) on dynamic posture.....	108
Table (15):	Comparison of the duration of improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on static posture.	110
Table (16):	Comparison of the duration of improvement of the forehead horizontal lines between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on dynamic posture.....	110
Table (17):	Comparison of the duration of improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on static posture.	112
Table (18):	Comparison of the duration of improvement of the crow's feet wrinkles between the right side (ONA-treated) and the left side (ABO-treated) among group B patients (ABO: ONA; 3.0: 1.0 U) on dynamic posture.....	112
Table (19):	Comparison between the right side (ONA-treated) and the left side (ABO-treated) of the forehead regarding the severity of wrinkles among group A (ABO: ONA; 2.5: 1.0 U) patients on static posture.....	115

List of Tables *(Cont...)*

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (20):	Comparison between the right side (ONA-treated) and the left side (ABO-treated) of the forehead regarding the severity of wrinkles among group A (ABO: ONA; 2.5: 1.0 U) patients on dynamic posture.	119
Table (21):	Comparison between the right crow's feet (ONA-treated) and the left crow's feet (ABO-treated) regarding the severity of wrinkles among group A (ABO: ONA; 2.5: 1.0 U) patients on static posture.....	123
Table (22):	Comparison between the right crow's feet (ONA-treated) and the left crow's feet (ABO-treated) regarding the severity of wrinkles among group A (ABO: ONA; 2.5: 1.0 U) patients on dynamic posture.	126
Table (23):	Comparison between the right side (ONA-treated) and the left side (ABO-treated) of the forehead regarding the severity of wrinkles among group B (ABO: ONA; 3.0: 1.0 U) patients on static posture.....	130
Table (24):	Comparison between the right side (ONA-treated) and the left side (ABO-treated) of the forehead regarding the severity of wrinkles among group B (ABO: ONA; 3.0: 1.0 U) patients on dynamic posture.	134
Table (25):	Comparison between the right crow's feet (ONA-treated) and the left crow's feet (ABO-treated) regarding the severity of wrinkles among group B (ABO: ONA; 3.0: 1.0 U) patients on static posture.....	138

List of Tables *(Cont...)*

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (26):	Comparison between the right crow's feet (ONA-treated) and the left crow's feet (ABO-treated) regarding the severity of wrinkles among group B (ABO: ONA; 3.0: 1.0 U) patients on dynamic posture.	142
Table (27):	Comparison of group A (ABO: ONA 2.5: 1.0 U) patient's satisfaction regarding the improvement in the right side (ONA-treated) and left side (ABO-treated) of the forehead horizontal lines.....	143
Table (28):	Comparison of group A (ABO: ONA; 2.5: 1.0 U) patient's satisfaction regarding the improvement in the right (ONA-treated) and left (ABO-treated) crow's feet wrinkles.....	144
Table (29):	Comparison of group B (ABO: ONA 3.0: 1.0 U) patient's satisfaction regarding the improvement in the right side (ONA-treated) and left side (ABO-treated) of the forehead horizontal lines.....	145
Table (30):	Comparison of group B (ABO: ONA; 3.0: 1.0 U) patient's satisfaction regarding the improvement in the right (ONA-treated) and left (ABO-treated) crow's feet wrinkles.....	146

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	A picture illustrating the structure of the progenitor 150 kDa botulinum neurotoxin molecule.....	47
Figure (2):	A picture illustrating the cleavage of the progenitor 150 kDa botulinum neurotoxin molecule.....	49
Figure (3):	A picture illustrating the normal mechanism of acetylcholine release, versus the mechanism of botulinum neurotoxin inhibiting the release of acetylcholine	52
Figure (4):	A picture illustrating the molecular targets of different botulinum neurotoxin serotypes	54
Figure (5):	Digital photographs of patient no. 7 in group B at days 0, 7, 30, and 120 post-injection from left to right. Rows: A-Forehead static, B-Forehead dynamic, C-Lt. Crow's feet static, D-Lt. Crow's feet dynamic, E-Rt. Crow's feet static, F-Rt. Crow's feet dynamic.	83
Figure (6):	Syringe used for injection.....	84
Figure (7):	Unilateral injecting points for forehead horizontal lines and crow's feet.	87
Figure (8):	The Merz photonumerical scales for forehead horizontal lines and crow's feet	89
Figure (9):	Digital photographs of patient no. 1 in group A at days 0, 7, 30, and 120 post-injection from left to right.....	93

List of Figures *(Cont...)*

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (10):	Digital photographs of a patient no. 2 in group A at days 0, 7, 30, and 120 post-injection from left to right.....	94
Figure (11):	Digital photographs of a patient no. 1 in group B at days 0, 7, 30, and 120 post-injection from left to right.....	95
Figure (12):	Digital photographs of a patient no. 10 in group B at days 0, 7, 30, and 120 post-injection from left to right.....	96
Figure (13):	Brow elevation evident in the photos of the crow's feet wrinkles on static posture at days 0, 30, and 120.	145

Introduction

A large body of research has documented that, in our society, physical appearance has a significant impact on how individuals are perceived by others, and also that it is intrinsically linked to body image, self-esteem and confidence. Thus, it was concluded that an attractive physical appearance can be expected to result in an improved psychological well-being and an improved social functioning (*Finn et al., 2003*). This explains why, throughout history and across virtually all cultures, individuals have always desired and sought to improve and enhance their physical appearance (*Dessy et al., 2011*).

The face is the central focus of the perception of beauty and attractiveness. Thus, it is the facial appearance that represents the corner stone of the world wide aesthetic concern (*Finn et al., 2003*).

When the effects of aging on the face are addressed, the main topic of the discussion is always the wrinkles (*Zimblet et al., 2001*). In addition, facial wrinkles can send an emotional message and hence cause a negative impact on the individual's both societal impressions and self-esteem (*Finn et al., 2003*). Nowadays, medical advances have provided an increasing number of surgical and minimally invasive treatment options available to smooth these lines (*Fagien, 1999*).

One of the most important modalities available for smoothening of the facial wrinkles is the botulinum toxins injection. Botulinum toxins represent the foundation of the minimally invasive aesthetic facial treatments. It began with the use of botulinum toxin to smooth the glabellar frown lines and then expanded to include other facial areas such as the forehead horizontal lines and the crow's feet wrinkles (*Carruthers et al., 2007*).

There are eight serotypes of the toxin. The two most common commercial preparations authorized for cosmetic use worldwide are the Onabotulinumtoxin A, approved by the US FDA in 2002 and commercially known as Botox, and the Abobotulinumtoxin A, approved by the US FDA in 2009 and commercially known as Dysport (*Hexsel et al., 2012*).

Botulinum toxin A is a zinc-dependant endopeptidase composed of a light (50kDa) and a heavy (100 kDa) chains linked by disulfide bond (*Aoki, 2005*). Onabotulinumtoxin A and Abobotulinumtoxin A differ in the carrier protein attached to the 150-kDa botulinum toxin A molecule. Although Onabotulinumtoxin A contains a 900-kDa carrier protein attached to the toxin, a 750-kDa carrier exists in Abobotulinumtoxin A (*Lowe et al., 2006*).

Few studies were found to compare the characteristics of these two formulations of botulinum toxin A regarding their equivalent doses (*Lowe et al., 2010*), with no previous comparison of 3.0: 1.0 U and 2.5: 1.0 U dosing ratio of Abobotulinum toxin A: Onabotulinum toxin A in treatment of facial wrinkles.